XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net revenues $ 3,878 $ 3,786 $ 7,539 $ 7,447
Cost of sales 2,082 1,992 4,161 3,913
Gross profit 1,796 1,794 3,378 3,534
Research and development expenses 240 228 473 453
Selling and marketing expenses 603 594 1,149 1,178
General and administrative expenses 307 313 602 609
Intangible assets impairments 63 51 241 199
Goodwill impairment 700 745 700 745
Other assets impairments, restructuring and other items 100 118 195 246
Legal settlements and loss contingencies 462 729 695 1,854
Other income (33) (34) (34) (87)
Operating income (loss) (646) (949) (644) (1,662)
Financial expenses, net 268 211 528 468
Income (loss) before income taxes (914) (1,160) (1,172) (2,131)
Income taxes (benefit) (16) (900) (35) (899)
Share in (profits) losses of associated companies, net (1) 0 (1) (21)
Net income (loss) (898) (259) (1,136) (1,211)
Net income (loss) attributable to non-controlling interests (35) (27) (68) (24)
Net income (loss) attributable to Teva $ (863) $ (232) $ (1,068) $ (1,187)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ (0.77) $ (0.21) $ (0.96) $ (1.07)
Diluted $ (0.77) $ (0.21) $ (0.96) $ (1.07)
Weighted average number of shares (in millions):        
Basic 1,120 1,110 1,118 1,109
Diluted 1,120 1,110 1,118 1,109